 The 18th annual conference of the Pharmaceutical Contract Management Group in Krakow on 9 September 2022 discussed the future of the clinical trial landscape. It was agreed that by 2050, if one works in clinical trials, they will be a data scientist. New technologies such as biologically engineered human cells and less reliance on animals will be used in pre-clinical modelling. Adaptive clinical development will be used to evaluate safety and efficacy of treatments. Patients may be involved in safety testing and reimbursement will be negotiated with regulators and pairs. This article was authored by Timothy C. Hardman, Rob Acheson, Richard Scafe, and others.